Tumor glucose metabolism and amino acid metabolism are usually enhanced, 18 F-FDG for
tumor glucose metabolism PET imaging has been clinically well known, but tumor amino …

Molecular imaging has witnessed a great progress in the field of oncology over the past few
decades. Radiolabeled amino acid (AA) tracers are particularly helpful in the areas where …

18F-labeled amino acids are an important class of imaging agents for positron emission
tomography (PET) that target the increased rates of amino acid transport by many tumor …

The currently preferred radiopharmaceutical for positron emission tomography (PET) in
oncology is 2-[18 F] fluoro-deoxyglucose (FDG). Increased accumulation of this …

There is a high demand for tumor specific PET tracers in oncology imaging. Besides
glucose, certain amino acids also serve as energy sources and anabolic precursors for …

Tumor cells have an increased nutritional demand for amino acids (AAs) to satisfy their rapid
proliferation. Positron-emitting nuclide labeled AAs are interesting probes and are of great …

With the increasing clinical application of FDG PET, interest in metabolic imaging in general
is growing among clinicians. The reasons for the great impact that FDG PET is currently …

With an incidence of 20.5 per 100,000 people each year, tumors of the central nervous
system are a heterogeneous group, with meningiomas (35.5%) and gliomas (30%) being …

Simple Summary The early detection and treatment of malignant brain tumors can
significantly improve the survival time and life quality of affected patients. Whereas positron …

Routine diagnostics and treatment monitoring of brain tumors is usually based on contrast-
enhanced magnetic resonance imaging (MRI). However, the capacity of structural MRI to …